Results 161 to 170 of about 2,758 (199)
Some of the next articles are maybe not open access.
Canadian Journal of Health Technologies, 2023
CADTH recommends that Ultomiris be reimbursed by public drug plans for the treatment of neuromyelitis optica spectrum disorder (NMOSD) if certain conditions are met. Ultomiris should only be covered to treat adult patients with anti–aquaporin 4 (AQP4) antibody–positive NMOSD.
openaire +1 more source
CADTH recommends that Ultomiris be reimbursed by public drug plans for the treatment of neuromyelitis optica spectrum disorder (NMOSD) if certain conditions are met. Ultomiris should only be covered to treat adult patients with anti–aquaporin 4 (AQP4) antibody–positive NMOSD.
openaire +1 more source
Ravulizumab: A Review in Generalised Myasthenia Gravis
Drugs, 2023Ravulizumab (ULTOMIRIS®) is the first long-acting complement C5 inhibitor (administered intravenously every 8 weeks) to be approved in several countries globally, for adults with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive (AChR Ab+).
openaire +2 more sources
Ravulizumab: First Global Approval
Drugs, 2019Ravulizumab (ravulizumab-cwvz; ULTOMIRIS™), a humanized monoclonal antibody, is a complement C5 inhibitor developed by Alexion Pharmaceuticals for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS).
openaire +2 more sources
Canadian Journal of Health Technologies
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire +1 more source
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire +1 more source
Ravulizumab-related meningococcal sepsis post rituximab
Practical NeurologyComplement inhibition is a highly effective strategy for preventing relapse and disability accumulation in neuromyelitis optica spectrum disorder (NMOSD). Invasive infection with Neisseria meningitidis , the principal risk of complement inhibition, is largely mitigated by adequate vaccination.
Katharine Kline +8 more
openaire +1 more source
Ravulizumab Treatment during Pregnancy: A Case Report
BloodParoxysmal nocturnal hemoglobinuria (PNH) is a rare chronic blood disorder associated with a significant risk of thrombosis, the leading cause of death in patients (pts) with PNH. In pregnant women, PNH is also associated with increased maternal and fetal complications. While data are available for eculizumab (ECU)
Daniel Knight, Bhumika J Patel
openaire +1 more source
Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis
Journal of Neurology, 2023Tuan Vu +2 more
exaly